The Center for Neurologic Study, a nonprofit 501C3 corporation, is a leader in an area now referred to as Translational Medicine. Recently, our director, along with colleagues, were awarded the international Healey Prize for their drug discovery efforts. This was based on the development of antisense molecules (ASOs) that represent a major opportunity to treat heritable diseases of the nervous system, such as familial amyotrophic lateral sclerosis. Further, we are pleased to announce the publication of Neurotherapeutics in the Era of Translational Medicine, which Dr. Smith co-edited with Clive Svendsen and Brian Kaspar (see publications).
The seminal discovery of DMQ at CNS resulted in the development of Nuedexta. The drug, ultimately formulated by Avanir Pharmaceuticals Corporation, was approved by FDA for the treatment of labile emotionality that occurs in association with numerous neurological disorders. Recently, Nuedexta was demonstrated to enhance speech and swallowing in patients with ALS. The results were published in the Journal of Neurotherapeutics (see publications). To our knowledge, this placebo-controlled trial is the first to demonstrate the enhancement of any function in this disease.
For those who have followed CNS over the years, we are pleased to announce a new direction for the foundation: the establishment of an angel investing fund. The purpose of the fund is to invest in seed stage preclinical drug, biomarker, and device development in the area of neurodegenerative disorders. This year, we have provided seed funding for two companies.
The Center’s research collaborations are extensive. As in instances in which we invest in early stage technology, our efforts, focused on advancing treatments and cures for neurodegenerative disorders, are similarly innovative.
Our success is due in part to the support we have received from individuals, corporations and foundations. If you’ve come upon us, consider making a donation, if not to us, make a donation to the cause that concerns you.